Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs
Author:
Funder
Shenzhen SZSITIC
National NSF of China
NSF Project of CQ CSTC
Singapore Academic Research Fund
Publisher
Elsevier BV
Subject
Pharmacology
Reference73 articles.
1. Targeting multidrug resistance in cancer;Szakacs;Nat. Rev. Drug Discov.,2006
2. Cancer drug resistance: an evolving paradigm;Holohan;Nat. Rev. Cancer,2013
3. Genetic heterogeneity and cancer drug resistance;Turner;Lancet Oncol.,2012
4. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer;Ng;Nat. Med.,2012
5. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors;Wilson;Nature,2012
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring physicochemical characteristics of cyclodextrin through M-polynomial indices;Scientific Reports;2024-08-28
2. Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery;International Journal of Molecular Sciences;2024-07-28
3. Geraniol and citral: recent developments in their anticancer credentials opening new vistas in complementary cancer therapy;Zeitschrift für Naturforschung C;2024-04-19
4. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia;International Journal of Pharmaceutics;2024-04
5. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3